Adma Biologics Inc (ADMA) News

Hopefully we can gather some institutional interest

Monk I hinted about the earnings…… unbelievable day. I did take some profit today finally. But I’m still good

ADMA 9.00

ADMA new 52 week high

Monk hit 7.97 after hours!!!!

Not going to happen. I’ll wait for earnings

Monk can we break 7.00 before earnings??

ADMA new 52 high

Thanks for the heads up
As a sector, the medtech stocks peaked in February
But there always exceptions

Earnings next week. Could get very I teresting

ADMA new 52 week high

ADMA new 52 hi
Next settlement begins 5/28 per SEC mandate

YES
Next day settlement begins 5/28 per SEC mandate

Monk new high!!

Going to be choppy here for a while before next move up

ADMA new 52 hi

ADMA new 52 week high

We crossed 6.00 !!

ADMA new 52 week high

Thursdays trading should be interesting

ADMA new 52 week high

ADMA new 52 week high

Let’s watch it after earnings report. Maybe cross 6.00

ADMA new 52 week high

ADMA new 52 week high

Just raised estimates for the quarter again.

https://www.otcmarkets.com/stock/ADMA

Record earnings and finally cash flow positive!!

https://www.otcmarkets.com/stock/ADMA

https://www.otcmarkets.com/stock/ADMA

ADMA
Adma Biologics Inc
4.48
0.17 (3.94%)
Volume: 2,863,049
Day Range: 4.305 - 4.49
Last Trade Time: 7:15:23 PM EDT

Great earnings!!

ADMA
Adma Biologics Inc
3.5402
0.0202 (0.57%)
Volume: 1,095,424
Day Range: 3.53 - 3.66
Last Trade Time: 6:38:45 PM EDT

ADMA
Adma Biologics Inc
3.87
-0.01 (-0.26%)
Volume: 3,741,501
Day Range: 3.815 - 3.90
Last Trade Time: 5:40:25 PM EDT

ADMA
Adma Biologics Inc
4.05
0.11 (2.79%)
Volume: 1,745,491
Day Range: 3.87 - 4.10
Last Trade Time: 7:58:47 PM EDT

ADMA
Adma Biologics Inc
4.05
0.11 (2.79%)
Volume: 1,745,491
Day Range: 3.87 - 4.10
Last Trade Time: 7:58:47 PM EDT

yes, https://www.otcmarkets.com/stock/ADMA/overview

up very nicely today, to a new 2 wk high. Glad my GTC order to sell some at $3.98 expired a few days ago!

ADMA
Adma Biologics Inc
3.35
0.04 (1.21%)
Volume: 1,641,755
Day Range: 3.26 - 3.39
Last Trade Time: 5:57:27 PM EDT

ad-ma ADMA
Adma Biologics Inc
3.19
-0.03 (-0.93%)
Volume: 1,787,099
Day Range: 3.07 - 3.22
Last Trade Time: 7:25:20 PM EDT

ADMA
Adma Biologics Inc
3.42
-0.08 (-2.29%)
Volume: 1,322,269
Day Range: 3.42 - 3.49
Last Trade Time: 7:40:10 PM EST

Looks like a double pointed top forming I think is a bearish sign

Look at the weekly and monthly charts for the trend

Every time there is positive news this stock tanks?????

ADMA Biologics receives FDA approval for its eighth plasma collection center, located in Hammond, LA

This plasma collection facility commenced operations and initiated source plasma collection in the second quarter of 2022. With the FDA approval announced today, this facility is now licensed to collect, and introduce into interstate commerce, human source plasma for further manufacturing in the U.S.

ADMA
Adma Biologics Inc
3.818
0.018 (0.47%)
Volume: 2,486,357
Day Range: 3.735 - 3.88
Last Trade Time: 7:02:33 PM EST

ADMA
Adma Biologics Inc
3.818
0.018 (0.47%)
Volume: 2,486,357
Day Range: 3.735 - 3.88
Last Trade Time: 7:02:33 PM EST

looks like head & shoulder formng

ADMA
Adma Biologics Inc
3.58
0.02 (0.56%)
Volume: 4,700,099
Day Range: 3.51 - 3.62
Last Trade Time: 7:58:51 PM EST

ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters Option to Purchase Additional Shares


ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, in addition to the exercise in full of the underwriters' option to purchase an additional 3,146,853 shares of common stock. The gross proceeds from the exercise of the overallotment option were $9 million, bringing the total gross proceeds to ADMA from the offering to $69 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

ADMA intends to use the net proceeds from this offering to accelerate commercialization and production activities, complete plasma center buildout and obtain FDA approvals, to conclude post FDA marketing approval research and development projects, and for working capital, capital expenditures and for general corporate purposes.

Raymond James & Associates, Inc., Cantor Fitzgerald & Co. and Mizuho Securities USA LLC acted as joint book-running managers of the offering.

The offering of the securities described above was made by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-256643) previously filed with the Securities and Exchange Commission ("SEC") and declared effective by the SEC on August 3, 2021. The final prospectus supplement, including the accompanying prospectus, relating to the offering was filed with the SEC on December 7, 2022 and is available on the SEC's website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, or by telephone at (800) 248-8863, or e-mail at prospectus@raymondjames.com, or from Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at prospectus@cantor.com, or from Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020, by email at US-ECM@us.mizuho-sc.com, or by telephone at (212) 205-7600.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such